J. Safra Sarasin Holding AG Increases Position in DexCom, Inc. $DXCM

by · The Markets Daily

J. Safra Sarasin Holding AG lifted its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 26.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,041 shares of the medical device company’s stock after acquiring an additional 9,758 shares during the period. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $2,891,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Reflection Asset Management bought a new position in DexCom in the fourth quarter worth about $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom in the 1st quarter worth approximately $25,000. CVA Family Office LLC grew its position in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the last quarter. MCF Advisors LLC bought a new position in shares of DexCom during the 4th quarter worth approximately $32,000. Finally, ORG Partners LLC raised its stake in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,450 shares of company stock valued at $5,270,409 over the last ninety days. Corporate insiders own 0.28% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $76.35 on Tuesday. The company has a market cap of $29.46 billion, a price-to-earnings ratio of 32.63, a PEG ratio of 1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The stock’s fifty day moving average price is $69.95 and its 200 day moving average price is $68.51. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The firm’s revenue was up 15.0% compared to the same quarter last year. As a group, equities research analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DXCM. Benchmark reaffirmed a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a research note on Tuesday, March 24th. William Blair upgraded DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Finally, UBS Group set a $95.00 price target on DexCom in a report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $84.88.

Check Out Our Latest Stock Analysis on DXCM

DexCom Company Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).